Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.

Epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFR-TKIs) have become first-line drugs used for non-small cell lung cancer (NSCLC) treatment. However, drug resistance to EGFR-TKIs will be developed inevitably due to the repeated use of these drugs. In the present study, we isolated cancer stem cells (CSCs) from the PC9 NSCLC cell line. We then observed that the PC9 CSCs showed significant resistance to erlotinib compared with the PC9 non-CSCs. Erlotinib failed to suppress the phosphorylation of PI3K and AKT in PC9 CSCs, although the EGFR was inhibited sufficiently. Mechanically, we observed aberrant upregulation of microRNA-23a (miR-23a) and downregulation of PTEN in PC9 CSCs compared to PC9 non-CSCs. Luciferase reporter assays proved that PTEN was the target of miR-23a in PC9 CSCs. Furthermore, knockdown of miR-23a enhanced the antitumor effect of erlotinib by increasing the expression of PTEN. In addition, transfection with miR-23a inhibitors promoted the erlotinib-dependent inhibition of PI3K/AKT pathway, thus, suppressing the proliferation and inducing apoptosis in PC9 CSCs. These results propose that upregulation of miR-23a is a potential mechanism associated with resistance to EGFR-TKIs in lung cancer stem cells. Inhibition of miR-23a serves as a novel therapeutic strategy to eliminate the EGFR-TKIs resistance of lung cancer stem cells.

[1]  Haiyang Xie,et al.  Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway. , 2016, International journal of oncology.

[2]  Fujun Qin,et al.  MiR-101 Targets the EZH2/Wnt/β-Catenin the Pathway to Promote the Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells , 2016, Scientific Reports.

[3]  Yangbai Sun,et al.  MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin treatment in osteosarcoma , 2016, Scientific Reports.

[4]  Yuehua Wu,et al.  MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway , 2016, Oncotarget.

[5]  S. Cheung,et al.  Octamer 4/microRNA‐1246 signaling axis drives Wnt/β‐catenin activation in liver cancer stem cells , 2016, Hepatology.

[6]  Juan Wang,et al.  MiR-29a Regulates Radiosensitivity in Human Intestinal Cells by Targeting PTEN Gene , 2016, Radiation Research.

[7]  Ran Wang,et al.  Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway , 2016, Scientific Reports.

[8]  Ying-Ying Luo,et al.  MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer , 2016, Tumor Biology.

[9]  Kazuhisa Takahashi,et al.  Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. , 2016, Biochemical and biophysical research communications.

[10]  X. Gong,et al.  Ferulic acid inhibits proliferation and promotes apoptosis via blockage of PI3K/Akt pathway in osteosarcoma cell. , 2016, American journal of translational research.

[11]  Yuhchyau Chen,et al.  IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer , 2015, Oncotarget.

[12]  Xiaohua Zhang,et al.  miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis , 2016, Tumor Biology.

[13]  Xiaobo Wang,et al.  Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer , 2016, Tumor Biology.

[14]  R. Clarkson,et al.  Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL , 2015, Molecular Cancer.

[15]  Yihui Ma,et al.  Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. , 2015, International journal of clinical and experimental pathology.

[16]  Lei Liu,et al.  Clinical value of microRNA-23a upregulation in non-small cell lung cancer. , 2015, International journal of clinical and experimental medicine.

[17]  Zhiwei Zhang,et al.  miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. , 2015, Oncology reports.

[18]  Helena Carreira,et al.  Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) , 2015, The Lancet.

[19]  Kazuhisa Takahashi,et al.  Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor , 2014, PloS one.

[20]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[21]  W. Pao,et al.  Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer , 2013, Nature Reviews Clinical Oncology.

[22]  A. Wozniak,et al.  Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. , 2013, Clinical lung cancer.

[23]  A. Gargalionis,et al.  Insights in microRNAs biology. , 2013, Current topics in medicinal chemistry.

[24]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[25]  H. Xia,et al.  MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[26]  P. Pandolfi,et al.  Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. , 2011, Cancer cell.

[27]  John D Minna,et al.  Molecular biology of lung cancer: clinical implications. , 2002, Clinics in chest medicine.

[28]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[29]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[30]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[32]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[33]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[34]  M. Ladanyi,et al.  Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.

[35]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[36]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.